Published in Am J Pathol on September 01, 2000
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood (2010) 4.02
The biology of Hodgkin's lymphoma. Nat Rev Cancer (2008) 3.31
The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood (2005) 2.99
Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia (2004) 1.92
Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem (2008) 1.92
Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer (2005) 1.59
The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. Neoplasia (2005) 1.42
Hodgkin lymphoma. J Clin Invest (2012) 1.41
Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia (2005) 1.34
Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol (2004) 1.28
EZH2 in normal and malignant hematopoiesis. Leukemia (2013) 1.28
Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J Cancer Res Clin Oncol (2008) 1.21
EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World J Gastroenterol (2010) 1.19
Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. Cancer Res (2011) 1.16
miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. Am J Pathol (2012) 1.13
Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res (2007) 1.07
The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival. Carcinogenesis (2009) 1.06
Clinicopathologic characteristics of high expression of Bmi-1 in esophageal adenocarcinoma and squamous cell carcinoma. BMC Gastroenterol (2012) 0.90
Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Med Res Rev (2015) 0.88
A small molecule inhibitor of polycomb repressive complex 1 inhibits ubiquitin signaling at DNA double-strand breaks. J Biol Chem (2013) 0.88
The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer. J Mol Histol (2006) 0.88
Site-specific expression of polycomb-group genes encoding the HPC-HPH/PRC1 complex in clinically defined primary nodal and cutaneous large B-cell lymphomas. Am J Pathol (2004) 0.88
Polycomb-group proteins are involved in silencing processes caused by a transgenic element from the murine imprinted H19/Igf2 region in Drosophila. Dev Genes Evol (2003) 0.83
An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nat Med (2016) 0.83
Expression and clinicopathological significance of Mel-18 and Bmi-1 mRNA in gastric carcinoma. J Exp Clin Cancer Res (2010) 0.81
The epigenetic basis of diffuse large B-cell lymphoma. Semin Hematol (2015) 0.78
Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B. World J Gastroenterol (2015) 0.77
Polycomb Repressive Complex 2 regulates lineage fidelity during embryonic stem cell differentiation. PLoS One (2014) 0.77
Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2. Cancer Discov (2016) 0.75
The JAZF1/SUZ12 fusion protein disrupts PRC2 complexes and impairs chromatin repression during human endometrial stromal tumorogenesis. Oncotarget (2016) 0.75
Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer? Cold Spring Harb Mol Case Stud (2017) 0.75
EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop. Nat Commun (2017) 0.75
The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature (1999) 12.60
Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell (1991) 7.16
Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev (1994) 6.10
Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev (1999) 5.35
Polycombing the genome: PcG, trxG, and chromatin silencing. Cell (1998) 3.97
Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes. Mol Cell Biol (1998) 3.30
Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature (1982) 3.26
Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex. Genes Dev (1997) 2.96
Locking in stable states of gene expression: transcriptional control during Drosophila development. Curr Opin Cell Biol (1995) 2.75
Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med (1996) 2.75
CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell (1993) 2.73
Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood (1995) 2.57
Interaction of mouse polycomb-group (Pc-G) proteins Enx1 and Enx2 with Eed: indication for separate Pc-G complexes. Mol Cell Biol (1998) 2.17
Functions of mammalian Polycomb group and trithorax group related genes. Curr Opin Genet Dev (1997) 2.12
Pertubation of B and T cell development and predisposition to lymphomagenesis in Emu Bmi1 transgenic mice require the Bmi1 RING finger. Oncogene (1997) 1.98
Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell proliferation. Genes Dev (1999) 1.95
Identification and characterization of interactions between the vertebrate polycomb-group protein BMI1 and human homologs of polyhomeotic. Mol Cell Biol (1997) 1.89
Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers. J Immunol (2000) 1.83
RING1 is associated with the polycomb group protein complex and acts as a transcriptional repressor. Mol Cell Biol (1997) 1.83
Rapid synthesis of biotin-, digoxigenin-, trinitrophenyl-, and fluorochrome-labeled tyramides and their application for In situ hybridization using CARD amplification. J Histochem Cytochem (1998) 1.82
Polycomb group protein complexes: do different complexes regulate distinct target genes? Biochim Biophys Acta (1999) 1.75
Interference with the expression of a novel human polycomb protein, hPc2, results in cellular transformation and apoptosis. Mol Cell Biol (1997) 1.74
Ring1A is a transcriptional repressor that interacts with the Polycomb-M33 protein and is expressed at rhombomere boundaries in the mouse hindbrain. EMBO J (1997) 1.67
Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood (1999) 1.66
Stage-specific expression of polycomb group genes in human bone marrow cells. Blood (1998) 1.62
RING1 interacts with multiple Polycomb-group proteins and displays tumorigenic activity. Mol Cell Biol (1999) 1.55
Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood (1988) 1.55
Hodgkin's disease with a B-cell phenotype often shows a VDJ rearrangement and somatic mutations in the VH genes. Blood (1994) 1.26
Germinal centers: form and function. Curr Opin Immunol (1998) 1.22
The role of mel-18, a mammalian Polycomb group gene, during IL-7-dependent proliferation of lymphocyte precursors. Immunity (1997) 1.16
Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. Blood (1998) 1.16
Reed-Sternberg cell genome expression supports a B-cell lineage. Blood (1999) 1.14
mel-18 negatively regulates cell cycle progression upon B cell antigen receptor stimulation through a cascade leading to c-myc/cdc25. Immunity (1998) 0.98
Reed-Sternberg cell: survival in a hostile sea. Lab Invest (1998) 0.97
Immunohistochemical evidence of abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin's disease and CD30+ anaplastic lymphomas. Hematol Pathol (1991) 0.96
Gene expression by single Reed-Sternberg cells: pathways of apoptosis and activation. Blood (1998) 0.91
Cellular origin and clonality of classic Hodgkin's lymphoma: immunophenotypic and molecular studies. Semin Hematol (1999) 0.91
Generation of cells with Hodgkin's and Reed-Sternberg phenotype through downregulation of CD99 (Mic2). Blood (1998) 0.90
Heterogeneous expression of proto-oncogenes in Hodgkin's disease derived cell lines. Hematol Oncol (1990) 0.89
Expression of c-myc oncogene product and ras family oncogene products in various human malignant lymphomas defined by immunohistochemical techniques. Cancer (1988) 0.89
Clonal VDJ recombination of the immunoglobulin heavy chain gene by PCR in classical Hodgkin's disease. Am J Clin Pathol (1995) 0.87
Epstein-Barr virus in Hodgkin's disease: more than just an innocent bystander. J Pathol (1997) 0.84
Antiapoptotic marker Bcl-X(L), expression on Reed-Sternberg cells of Hodgkin's disease using a novel monoclonal marker, YTH-2H12. Hum Pathol (1999) 0.83
Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: involvement of apoptosis resistance? Mod Pathol (1998) 0.82
Expression of c-myc and c-ras oncogenes in the neoplastic and non-neoplastic cells of Hodgkin's disease. Eur J Haematol (1995) 0.82
Identifying the precursors of Hodgkin and Reed-Sternberg cells in Hodgkin's disease: role of the germinal center in B-cell lymphomagenesis. J Acquir Immune Defic Syndr (1999) 0.82
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol (1995) 10.07
A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol (1997) 6.09
Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet (1999) 5.58
Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet (1999) 4.24
The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol (1990) 4.09
Sexually transmitted infection as a cause of anal cancer. N Engl J Med (1997) 4.05
Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes. Mol Cell Biol (1998) 3.30
The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer (1995) 3.29
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet (1999) 3.25
Rapid detection of human papillomavirus in cervical scrapes by combined general primer-mediated and type-specific polymerase chain reaction. J Clin Microbiol (1990) 3.21
Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol (1995) 3.20
K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med (1990) 3.16
Human papillomavirus--the most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer (1996) 2.91
Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer (2000) 2.86
Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens. Sex Transm Infect (2001) 2.85
The drug resistance-related protein LRP is the human major vault protein. Nat Med (1995) 2.78
General primer-mediated polymerase chain reaction permits the detection of sequenced and still unsequenced human papillomavirus genotypes in cervical scrapes and carcinomas. Int J Cancer (1990) 2.69
Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer (1993) 2.60
Direct detection and genotyping of Chlamydia trachomatis in cervical scrapes by using polymerase chain reaction and restriction fragment length polymorphism analysis. J Clin Microbiol (1993) 2.59
Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood (2001) 2.54
Serotyping and genotyping of genital Chlamydia trachomatis isolates reveal variants of serovars Ba, G, and J as confirmed by omp1 nucleotide sequence analysis. J Clin Microbiol (1998) 2.47
ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol (2000) 2.43
Endothelial cell chimerism after renal transplantation and vascular rejection. Lancet (2001) 2.35
The human polycomb group complex associates with pericentromeric heterochromatin to form a novel nuclear domain. J Cell Biol (1998) 2.29
Immunoglobulin containing cells in inflammatory bowel disease of the colon: a morphometric and immunohistochemical study. Gut (1980) 2.24
Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer (1994) 2.23
Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl (2000) 2.23
RNA amplification by nucleic acid sequence-based amplification with an internal standard enables reliable detection of Chlamydia trachomatis in cervical scrapings and urine samples. J Clin Microbiol (1996) 2.22
The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol (2001) 2.21
Causes of cervical cancer in the Philippines: a case-control study. J Natl Cancer Inst (1998) 2.19
Campylobacter colitis: histological immunohistochemical and ultrastructural findings. Gut (1985) 2.15
PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer (1996) 2.13
Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiol Biomarkers Prev (1997) 2.12
Processing of long-stored archival cervical smears for human papillomavirus detection by the polymerase chain reaction. Br J Cancer (1995) 2.00
The polycomb group protein EED interacts with YY1, and both proteins induce neural tissue in Xenopus embryos. Mol Cell Biol (2001) 1.98
Improved PCR sensitivity for direct genotyping of Chlamydia trachomatis serovars by using a nested PCR. J Clin Microbiol (1994) 1.97
C-Terminal binding protein is a transcriptional repressor that interacts with a specific class of vertebrate Polycomb proteins. Mol Cell Biol (1999) 1.97
Use of anticontamination primers in the polymerase chain reaction for the detection of human papilloma virus genotypes in cervical scrapes and biopsies. J Med Virol (1989) 1.95
C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation (1997) 1.94
Difference in prevalence of human papillomavirus genotypes in cytomorphologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia. Int J Cancer (1991) 1.89
Identification and characterization of interactions between the vertebrate polycomb-group protein BMI1 and human homologs of polyhomeotic. Mol Cell Biol (1997) 1.89
High endothelial differentiation in human lymphoid and inflammatory tissues defined by monoclonal antibody HECA-452. Am J Pathol (1988) 1.86
Tissue distribution of the multidrug resistance protein. Am J Pathol (1996) 1.84
Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers. J Immunol (2000) 1.83
RING1 is associated with the polycomb group protein complex and acts as a transcriptional repressor. Mol Cell Biol (1997) 1.83
Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood (1997) 1.82
Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer (2001) 1.82
In situ localization of lymphocyte subsets in synovial membranes of patients with rheumatoid arthritis with monoclonal antibodies. J Rheumatol (1982) 1.78
Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance. Int J Cancer (1988) 1.78
Sarcomatoid carcinoma of the urinary bladder. Clinicopathologic analysis of 18 cases with immunohistochemical and electron microscopic findings. Am J Surg Pathol (1994) 1.76
Polycomb group protein complexes: do different complexes regulate distinct target genes? Biochim Biophys Acta (1999) 1.75
Interference with the expression of a novel human polycomb protein, hPc2, results in cellular transformation and apoptosis. Mol Cell Biol (1997) 1.74
PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. J Clin Pathol (2000) 1.73
Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res (1994) 1.73
Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. Cancer Res (2000) 1.72
The viral origin of cervical cancer in Rabat, Morocco. Int J Cancer (1998) 1.69
Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med (1994) 1.69
Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma. Oncogene (2006) 1.69
Chlamydia trachomatis and ectopic pregnancy: retrospective analysis of salpingectomy specimens, endometrial biopsies, and cervical smears. J Clin Pathol (1995) 1.69
Ring1A is a transcriptional repressor that interacts with the Polycomb-M33 protein and is expressed at rhombomere boundaries in the mouse hindbrain. EMBO J (1997) 1.67
Analysis of cytomorphologically abnormal cervical scrapes for the presence of 27 mucosotropic human papillomavirus genotypes, using polymerase chain reaction. Int J Cancer (1994) 1.67
Small cell carcinoma of the urinary bladder. A clinicopathologic, morphometric, immunohistochemical, and ultrastructural study of 18 cases. Cancer (1989) 1.65
The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium. J Immunol (1991) 1.63
Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. Cancer Res (1999) 1.63
Determination of Chlamydia trachomatis prevalence in an asymptomatic screening population: performances of the LCx and COBAS Amplicor tests with urine specimens. J Clin Microbiol (1999) 1.60
Low diagnostic accuracy of selective screening criteria for asymptomatic Chlamydia trachomatis infections in the general population. Sex Transm Infect (2000) 1.58
Mailed, home-obtained urine specimens: a reliable screening approach for detecting asymptomatic Chlamydia trachomatis infections. J Clin Microbiol (1999) 1.58
Urogenital Chlamydia trachomatis serovars in men and women with a symptomatic or asymptomatic infection: an association with clinical manifestations? J Clin Microbiol (2000) 1.58
Classification of primary cutaneous T-cell lymphomas. Histopathology (1994) 1.56
Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet (2001) 1.56
RING1 interacts with multiple Polycomb-group proteins and displays tumorigenic activity. Mol Cell Biol (1999) 1.55
Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol (1997) 1.54
Risk factors for cervical cancer in Thailand: a case-control study. J Natl Cancer Inst (1998) 1.53
HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer (2012) 1.53